FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] The company is operating in lab testing segment that is highly competitive and fragmented. Though it posted growth in its top and bottom lines for the reported periods, the sustainability of such margins going forward is a major concern. Based on its FY24 super earnings, the issue appears aggressively priced. There is no harm in skipping this pricey bet. Read detail review...
Qualitek Labs Limited peer comparison with similar listed entities. (As on March 31, 2023)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Qualitek Labs Limited | 5.49 | 5.49 | 24.74 | 18.21 | 30.10 | 4.04 | |
Choksi Laboratories Ltd. | 4.69 | 11.74 | 6.58 |
Notes:
Qualitek Labs IPO Reviews, analysis and views by popular members. Read Qualitek Labs Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 1 |
% | 0.00 | 0.00 | 0.00 | 100.00 |
Member | Review |
---|---|
Architbhai |
Avoid risky January 22, 2024 10:10:37 PM |
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|